LMLLF (Pharmadrug) Shiller PE Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharmadrug Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharmadrug  (OTCPK:LMLLF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Pharmadrug Shiller PE Ratio Related Terms


Pharmadrug Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Pharmadrug's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmadrug Shiller PE Ratio Chart

Pharmadrug Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmadrug Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LMLLF vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmadrug's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmadrug Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmadrug's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharmadrug's Shiller PE Ratio falls into.



Pharmadrug Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pharmadrug's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Pharmadrug's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.001/132.2623*132.2623
=-0.001

Current CPI (Mar. 2026) = 132.2623.

Pharmadrug Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -8.523 102.002 -11.052
201609 -0.961 101.765 -1.249
201612 -0.100 101.449 -0.130
201703 -0.052 102.634 -0.067
201706 -0.053 103.029 -0.068
201709 0.000 103.345 0.000
201712 -0.049 103.345 -0.063
201803 -0.108 105.004 -0.136
201806 -0.160 105.557 -0.200
201809 -0.725 105.636 -0.908
201812 -0.114 105.399 -0.143
201903 -0.126 106.979 -0.156
201906 -0.179 107.690 -0.220
201909 0.053 107.611 0.065
201912 -0.299 107.769 -0.367
202003 -0.015 107.927 -0.018
202006 -0.093 108.401 -0.113
202009 -0.027 108.164 -0.033
202012 -0.097 108.559 -0.118
202103 -0.033 110.298 -0.040
202106 -0.017 111.720 -0.020
202109 -0.022 112.905 -0.026
202112 0.062 113.774 0.072
202203 -0.028 117.646 -0.031
202206 -0.115 120.806 -0.126
202209 -0.012 120.648 -0.013
202212 -0.007 120.964 -0.008
202303 -0.003 122.702 -0.003
202306 -0.006 124.203 -0.006
202309 -0.004 125.230 -0.004
202312 -0.161 125.072 -0.170
202403 -0.004 126.258 -0.004
202406 -0.001 127.522 -0.001
202409 -0.001 127.285 -0.001
202412 -0.001 127.364 -0.001
202503 -0.001 129.181 -0.001
202506 -0.001 129.892 -0.001
202509 -0.001 130.287 -0.001
202512 -0.001 130.366 -0.001
202603 -0.001 132.262 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharmadrug Business Description

Other Exchanges PHRX:Canada
Address 130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5K 1H1
Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The company's operations comprise of the corporate division in Canada.